london euretina

This meeting has been awarded 20 CME credits

Security Notice

Please note that Kuoni are our only destination management company. Other venders indicating that are operating for the society should be ignored. We never use western union as a payment portal

Posters

Evaluation of pain during intravitreal Ozurdex injections versus intravitreal bevacizumab injections

Poster Details

First Author: M.Regenbogen ISRAEL

Co Author(s):    E. Moisseiev   M. Goldstein   A. Loewenstein            0   0 0   0 0   0 0   0 0

Abstract Details



Purpose:

: To evaluate the pain associated with intravitreal Ozurdex injections, and to compare it with that associated with intravitreal bevacizumab injections.

Setting:

Department of Ophthalmology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel. Affiliated to the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.

Methods:

The study included 57 eyes of 57 patients, who received an intravitreal Ozurdex injection at our institution. Pain was measured by the visual analog scale (VAS). Additional parameters recorded included age, sex, indication for the injection, number of previous Ozurdex injections in the study eye, presence of diabetes mellitus and lens status. Data was compared to a 2:1 sex- and age-matched control group of 114 patients who received intravitreal bevacizumab injections.

Results:

Indications for injection included diabetic macular edema (40.4%), and macular edema secondary to central and branch retinal vein occlusion (28% and 31.6%, respectively). Pain scores on the VAS ranged from 0 to 90, with a mean of 20.8 ± 20.3. There was no significant difference in pain between Ozurdex and bevacizumab injections. Pseudophakia was correlated with increased pain in Ozurdex injections.

Conclusions:

This is the first series evaluating the pain associated with intravitreal Ozurdex injections. Despite a larger needle gauge and tunneled injection technique, intravitreal injection of Ozurdex is not associated with increased pain compared to bevacizumab. This finding may be a potential advantage for Ozurdex, and may serve to improve patient compliance with future long-term treatment protocols.

Back to previous
EURETINA, Temple House, Temple Road, Blackrock, Co Dublin. | Phone: 00353 1 2100092 | Fax: 00353 1 2091112 | Email: euretina@euretina.org

Privacy policyHotel Terms and Conditions Cancellation policy